Brooks Laboratories accepts resignation of company secretary

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Brooks Laboratories accepts resignation of Company Secretary Ms. Krutika Rane
  • Effective date for cessation of duties is October 9, 2026
  • Reason cited is pursuit of alternate career opportunity outside organization
  • Disclosure made under Regulation 30 of SEBI Listing Regulations on September 16, 2026
powered bylight_fuzz_icon
51110821

*this image is generated using AI for illustrative purposes only.

Brooks Laboratories Limited has accepted the resignation of Ms. Krutika Rane as Company Secretary and Compliance Officer. Her departure is effective from the close of business on October 9, 2026.

Ms. Rane cited an alternate career opportunity outside the organization as the reason for her exit. The company disclosed this development in a filing dated September 16, 2026.

Regulatory Compliance

The intimation was issued in accordance with Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Brooks Laboratories informed both the BSE Limited and the National Stock Exchange of India Ltd regarding the change in Key Managerial Personnel.

Resignation Details

Ms. Rane submitted her resignation letter to the Board of Directors on September 16, 2026. In her letter, she thanked the board for their support during her tenure and requested the necessary filings with the Registrar of Companies and stock exchanges to effectuate the resignation.

Particulars Details
Name Ms. Krutika Rane
Designation Company Secretary and Compliance Officer
Reason Alternate career opportunity
Effective Date October 9, 2026

Bhushan Singh Rana, Whole-Time Director, signed the disclosure on behalf of the company.

Historical Stock Returns for Brooks Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-3.28%-3.60%-2.23%+4.90%-61.24%-59.01%

Has Brooks Laboratories identified a successor for the Company Secretary role, and what is the expected timeline for appointment?

Could this leadership change in compliance signal any underlying internal governance issues or upcoming strategic shifts at the company?

How might the transition period affect Brooks Laboratories' ability to meet upcoming regulatory filing deadlines with SEBI?

Brooks Laboratories AGM resolutions pass with 99.99% shareholder support

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Brooks Laboratories published final e-voting results for its 24th AGM held on September 3, 2026
  • All six ordinary resolutions passed with support exceeding 99.99% from participating shareholders
  • Total votes polled stood at 18,555,905, representing full participation from promoter and public non-institutional holders
  • Key approvals included FY26 financials, director reappointment, and executive remuneration
powered bylight_fuzz_icon
49982112

*this image is generated using AI for illustrative purposes only.

Brooks Laboratories has released the final e-voting results for its 24th Annual General Meeting (AGM), confirming that all six ordinary resolutions were approved by shareholders. The meeting, held on September 3, 2026, via video conference, saw near-unanimous support for the company’s financial statements and management appointments.

The scrutinizer report, issued by G.S. Sarin of Sharma Sarin & Associates on September 4, 2026, details the voting breakdown. A total of 18,555,905 votes were polled across all resolutions, representing 100% of the outstanding shares held by promoters and public non-institutional investors who participated.

Voting Results Breakdown

The voting process was conducted through remote e-voting and e-voting during the AGM. The promoter group held 15,500,292 shares, while public non-institutional shareholders held 3,055,613 shares. No institutional public shareholders voted.

Resolution Description Votes In Favour Votes Against % Support
1 Adoption of FY26 financial statements 18,555,826 79 99.9996%
2 Reappointment of Mr. Jitendra Pratap Singh 18,555,771 134 99.9993%
3 Ratification of cost auditor remuneration 18,555,826 79 99.9996%
4 Approval of related party transactions 18,555,826 79 99.9996%
5 Remuneration for Mr. Atul Ranchal 10,792,753 134 99.9988%
6 Remuneration for Mr. Rajesh Mahajan 10,818,497 134 99.9988%

Key Resolutions Passed

Shareholders approved the adoption of the annual audited standalone and consolidated financial statements for FY26. The reappointment of Mr. Jitendra Pratap Singh as a director, replacing those retiring by rotation, was also ratified.

Additionally, the meeting approved the remuneration for Mr. Atul Ranchal, President – Strategy, and Mr. Rajesh Mahajan, President – Trading, under Section 188(1)(f) of the Companies Act, 2013. Related party transactions and cost auditor remuneration were similarly approved.

Scrutinizer Report Details

The remote e-voting period commenced on August 31, 2026, at 9:00 am and concluded on September 2, 2026, at 5:00 pm. The votes were unblocked on September 3, 2026, in the presence of two independent witnesses. No invalid votes were recorded for Resolutions 1, 2, 3, and 4. For Resolutions 5 and 6, which involved related party interests, some promoter votes were marked invalid due to abstention requirements, though the resolutions still passed with overwhelming support from eligible voters.

Historical Stock Returns for Brooks Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-3.28%-3.60%-2.23%+4.90%-61.24%-59.01%

How might the near-unanimous shareholder approval of FY26 financial statements influence Brooks Laboratories' credit rating or future borrowing costs?

What strategic initiatives are Mr. Atul Ranchal and Mr. Rajesh Mahajan expected to prioritize following the ratification of their remuneration packages?

Could the complete absence of institutional public shareholders in the voting process signal a shift in investor sentiment or liquidity concerns for Brooks Laboratories?

More News on Brooks Laboratories

1 Year Returns:-61.24%